NarcA Art. 18f - In connection with medicinal cannabis products

Einleitung zur Rechtsnorm NarcA:

Art. 18f NarcA from 2023

Art. 18f ⁽¹⁾ In connection with medicinal cannabis products

¹ The FOPH shall operate an information system to process data under Article 8b.

² Doctors who treat persons with medicinal cannabis products must record the data required for data collection under Article 8b. Data on patients must be recorded in pseudonymised form.

³ The Federal Council shall specify:

a. the data required for data collection under Article 8b, in particular on side effects;

b. the frequency and time of data collection;

c. the doctors’ rights of access in accordance with paragraph 2;

d. the technical and organisational aspects of the data collection system;

e. the retention periods for the data;

f. the publication of the statistical analyses.

⁴ It may stipulate that data need no longer be recorded if new data is no longer required for the scientific evaluation under Article 8b paragraph 2.

⁽¹⁾ Inserted by No I of the FA of 19 March 2021, in force from 1 Aug. 2022 until 31 July 2029 (AS 2022 385; BBl 2020 6069).

Es besteht kein Anspruch auf Aktualität und Vollständigkeit/Richtigkeit.